Clinical Trial

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, phase II clinical study to evaluate the efficacy and safety of IN10018 in combination with PLD vs. placebo in combination with PLD in subjects with platinum-resistant recurrent ovarian cancer (including fallopian tube and primary peritoneal cancers).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-23.
Trial Details
NCT Number NCT06014528
Lead Sponsor InxMed (Shanghai) Co., Ltd.
Conditions Ovarian Cancer Recurrent
Enrollment 168 participants
Start Date 2022-09-06
Primary Completion 2026-12-24 (estimated)
Study Completion 2026-12-24 (estimated)
Updated on ClinicalTrials.gov 2025-04-30